11 Best Future Stocks to Buy Now

5. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Number of Hedge Fund Holders: 31 

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly.

At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly.

The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients.

Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth.